Carregant...
Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience
Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell malignancy, have dramatically improved. The development of the immunomodulatory drugs (IMiDs) which include thalidomide, lenalidomide, and pomalidomide, has contributed significantly to these improved outcomes....
Guardat en:
| Publicat a: | Drugs |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5705939/ https://ncbi.nlm.nih.gov/pubmed/28205024 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-017-0689-1 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|